GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC), announced today that the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has begun a Phase I clinical trial to test a novel vaccine known as Ad35HIV-EnvA to prevent HIV-1 infection. This adenovector-based vaccine was developed under a collaborative research and development agreement (CRADA) between GenVec and the VRC.
